Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?

被引:10
|
作者
Tachibana, Masahiro [1 ]
Yonemoto, Yukio [1 ]
Okamura, Koichi [1 ]
Suto, Takahito [1 ]
Sakane, Hideo [1 ]
Kaneko, Tetsuya [1 ]
Dam, Trang Thuy [1 ,2 ,3 ]
Okura, Chisa [1 ]
Tajika, Tsuyoshi [1 ]
Tsushima, Yoshito [3 ,4 ]
Chikuda, Hirotaka [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[2] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Showa Machi 3-39-15, Maebashi, Gunma 3718511, Japan
[3] Bach Mai Hosp, Radiol Ctr, Hanoi, Vietnam
[4] Gunma Univ Initiat Adv Res GIAR, Res Program Diagnost & Mol Imaging, Div Integrated Oncol Res, Maebashi, Gunma, Japan
关键词
Periodontitis; FDG-PET; CT; Biologic therapy; Rheumatoid arthritis; Treatment response; LARGE-JOINT DESTRUCTION; F-18-FDG ACCUMULATION; DISEASE; ASSOCIATION; IMMUNOTHERAPY; INFLAMMATION; ANTIBODIES; PET/CT;
D O I
10.1186/s13075-020-02269-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Rheumatoid arthritis (RA) and periodontitis (PD) have been suggested to share many clinical and pathological features. However, few reports have investigated the relationship between the degree of PD and the treatment response to RA. This study aimed to examine the relationship between the extent of PD and the treatment response to biologics in RA patients using FDG-PET/CT. Methods Sixty RA patients (male,n = 14; female,n = 46; average age, 58.3 years) treated with biologic agents were included in this study. FDG-PET/CT was performed at baseline and 6 months after the initiation of biological therapy. The maximum standardized uptake value (SUVmax) was used as a representative value for the assessment of the FDG uptake in periodontal tissue and joints including the bilateral shoulders, elbows, wrists, hip, knees, and ankle joints. The Disease Activity Score (DAS) 28-CRP and the following clinical parameters were assessed: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide antibody (ACPA), rheumatoid factor (RF), and matrix metalloproteinase 3 (MMP-3). The relationship between the treatment response of RA and the baseline SUVmax of the periodontal tissue was evaluated. Results The baseline periodontal SUVmax was related to patient age (r = 0.302,p = 0.009) and the ACPA level (r = 0.265,p = 0.025). The DAS28-CRP, CRP, ESR, MMP-3, and joint SUVmax values were significantly decreased after 6 months of biological therapy. However, the mean periodontal SUVmax, ACPA, and RF showed no significant changes after treatment. There was a significantly negative correlation between the baseline periodontal SUVmax and the treatment response of DAS28-CRP (r = - 0.369,p = 0.004). Conclusion There was a negative correlation between the extent of PD at baseline and the treatment response of RA patients who received biological therapy. The evaluation of the periodontal condition is considered to be an essential part for the management of RA.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Melatonin treatment does not improve rheumatoid arthritis
    Maestroni, Georges J.
    Otsa, Kati
    Cutolo, Maurizio
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 797 - 798
  • [32] EVOLUTION OF REGULATORY B CELLS UNDER TREATMENT BY BIOLOGICS IN RHEUMATOID ARTHRITIS
    Salomon, S.
    Guignant, C.
    Brault, C.
    Flahaut, G.
    Gubler, B.
    Fardellone, P.
    Marolleau, J.
    Goeb, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 905 - 905
  • [33] The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
    Joensuu, Jaana T.
    Huoponen, Saara
    Aaltonen, Kalle J.
    Konttinen, Yrjo T.
    Nordstrom, Dan
    Blom, Marja
    PLOS ONE, 2015, 10 (03):
  • [34] A NETWORK METANALYSIS COMPARING THE EFFICACY OF BIOLOGICS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS
    Bizzi, E.
    Petrella, L.
    Integlia, D.
    Migliorc, A.
    VALUE IN HEALTH, 2015, 18 (07) : A636 - A636
  • [35] Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics
    Contreras, Alejandro Escudero
    Carmen Castro-Villegas, M.
    Vanesa Hernandez-Hernandez, M.
    Diaz-Gonzalez, Federico
    REUMATOLOGIA CLINICA, 2011, 7 (06): : 392 - 396
  • [36] TIPS ON SELECTION OF BIOLOGICS FOR PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON TREATMENT PATTERNS
    Kamiya, M.
    Seen, S.
    Kikuchi, H.
    Okada, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1137 - 1137
  • [37] Comparison of the cost-efficacy of biologics in the treatment of rheumatoid arthritis.
    Chiou, CF
    Wanke, LA
    Reyes, C
    Malone, DC
    Ortmeier, BG
    Ofman, JJ
    Weisman, M
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S263 - S263
  • [38] EFFECT OF OBESITY IN RESPONSE TO BIOLOGICS IN RHEUMATOID ARTHRITIS
    Khan, A.
    Sukumaran, S.
    Kanitkar, M.
    Zafar, A. -S.
    Shah, S.
    Adnan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 821 - 822
  • [39] TREATMENT WITH ANTI-TNF BIOLOGICS IN PATIENT WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DOES NOT INCREASE THE RISK OF MALIGNANCY
    Fanto, M.
    Peragallo, M.
    Pietrosanti, M.
    Sorgi, M. L.
    Salemi, S.
    D'Amelio, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 438 - 438
  • [40] Treatment with biologics in Older Patients with Rheumatoid Arthritis - Results from the German Biologics Register Rabbit
    Strangfeld, A.
    Gaewert, L.
    Bussmann, A.
    Graessler, A.
    Wilden, E.
    Listing, J.
    Zink, A.
    AKTUELLE RHEUMATOLOGIE, 2009, 34 (05) : 291 - 298